Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies

NCT04152499 is registered in ClinicalTrials.gov with Klus Pharma Inc. as lead sponsor.

NCT NCT04152499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04152499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
Lead sponsor
Klus Pharma Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 28, 2020
Completion date
November 30, 2027
Enrollment
1,410 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, endometrial carcinoma, epithelial ovarian cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer, urothelial carcinoma